Roivant Sciences announced it will report its financial results for the second quarter ending September 30, 2026, on November 9, 2026, via a live conference call and webcast. The company will also hold an investor day on December 9, 2026, providing updates on its business and pipeline developments. Roivant is a biopharmaceutical company focused on developing and commercializing medicines, including FDA-approved LISRAYA™ and other late-stage candidates. Investors can access event details and archived webcasts on Roivant's website.
As of Oct 21, 2026 18:11 WIB, Roivant Sciences Ltd. shares (ROIV) are trading at USD 36.91 on Pluang, showing a strong 1-day gain of 5.70%. The company holds a market capitalization of $25.23 billion, reflecting significant investor interest ahead of its upcoming financial results announcement on November 9, 2026. Trading volume stands at 3,623,186 shares, with a typical hold time of 9 days, indicating active trading activity.
Immunovant, a clinical-stage immunology company, will announce its financial results for the second fiscal quarter ending September 30, 2026, on November 9 before the market opens. Roivant Sciences, its majority stockholder, will host a live conferen...
Brepocitinib, tested in two Phase 3 CLARITY trials for non-infectious uveitis (NIU), significantly outperformed placebo on all primary and key secondary endpoints, including longer time to treatment failure and steroid-free disease control. The drug ...
